NEW DELHI: The Supreme Court has questioned the Centre over the scope of its review of inflated medicine prices, raising concerns about whether regulatory scrutiny should extend beyond cancer drugs to other categories of medicines.
The development puts the spotlight on the wider issue of medicine affordability and the need for effective price regulation. The court’s intervention comes amid continuing concerns over the cost of treatment and the financial burden medical expenses place on patients and their families.
The Centre’s approach to reviewing medicine prices could have implications for consumers, pharmaceutical companies and the existing system of drug-price monitoring.
The proceedings underline the importance of examining pricing practices across a broader range of medicines rather than limiting the exercise to a single category. Further developments in the case are expected to clarify the scope of the government’s review.